Definition – What is squamous cell carcinoma of the lung? A cancer of the lung is generally referred to as bronchial carcinoma among medical professionals. However, these differ in the tissue type of the cancer. Adenocarcinomas and squamous cell carcinomas of the lung are frequent. An adenocarcinoma is a cancer that has developed from glandular … Squamous cell carcinoma of the lung?
Metastases/proliferation of squamous cell carcinoma of the lung Lung cancer is a cancer that often and readily metastasizes. Since the tumor is usually diagnosed late, in many cases a metastasis already exists at the time of diagnosis. Since in the case of a metastasis, the cancer has already spread throughout the body, a cure for … Metastases/proliferation of squamous cell carcinoma of the lung | Squamous cell carcinoma of the lung?
Treatment of squamous cell carcinoma of the lung The therapy depends on the stage of the cancer. In many cases, lung cancer is unfortunately detected very late, so that a radical therapy has to be carried out. In some cases it is unfortunately also no longer possible to cure the cancer. There are then only … Treatment of squamous cell carcinoma of the lung | Squamous cell carcinoma of the lung?
Stages of squamous cell carcinoma of the lung The stage classification is based on the size of the cancer and how far it has spread to lymph nodes or other organs. It is divided into stages 0-4. In stage 0, the tumor is still very small and only affects the uppermost layer.In stage 1 the … Stages of squamous cell carcinoma of the lung | Squamous cell carcinoma of the lung?
Products Nintedanib was approved in many countries in 2015 in soft capsule form (Ofev). Structure and properties Nintedanib (C31H33N5O4, Mr = 539.6 g/mol) is present in the drug as nintedanibesilate, a light yellow powder. Effects Nintedanib (ATC L01XE31) has antiproliferative and antitumor properties. It inhibits intracellular signaling pathways responsible for fibroblast proliferation, migration, and transformation. … Nintedanib
Health risks Tobacco smoking is one of the greatest threats to public health. The WHO estimates that up to 6 million people worldwide die prematurely from it each year, 600,000 of them from passive smoking. For Switzerland, the figure is around 9,000 deaths per year. And yet, about 28% of the population still smokes today, … Smoking: How does it affect your health?
Symptoms Chronic exposure to radon is the second leading cause of lung cancer after smoking. The cancer does not develop immediately, but after years or decades. It is estimated that 200 to 300 people die each year in many countries from lung cancer caused by radon. In Germany, the number of victims per year is … Radon
Products Lorlatinib was approved in the form of film-coated tablets in the United States in 2018, in the EU in 2019, and in many countries in 2020 (Lorviqua, or Lorbrena in the United States). Structure and properties Lorlatinib (C21H19FN6O2, Mr = 406.4 g/mol) exists as a white powder. Effects Lorlatinib (ATC L01XE44) has antitumor and … Lorlatinib
Products Nivolumab was approved in the United States in 2014 and in the in many countries and the EU in 2015 as a concentrate for the preparation of an infusion solution (Opdivo). Structure and properties Nivolumab is a human monoclonal antibody. It is an IgG4κ-immunoglobulin with a molecular mass of 146 kDa. Nivolumab is produced … Nivolumab
Products Erlotinib is commercially available in the form of film-coated tablets (Tarceva). It has been approved in many countries since 2005. Generic versions were registered in 2018. Structure and properties Erlotinib (C22H23N3O4, Mr = 393.4 g/mol) is present in drugs as erlotinib hydrochloride, a white powder that is sparingly soluble in water. Solubility increases with … Erlotinib
Products Ceritinib is commercially available in capsule form (Zykadia). It was approved in the United States in 2014 and in the EU and many countries in 2015. In 2020, film-coated tablets were registered. Structure and properties Ceritinib (C28H36N5O3ClS, Mr = 558.14 g/mol) exists as a white to slightly yellow or slightly brown powder. Effects Ceritinib … Ceritinib
Products Bevacizumab is commercially available as a concentrate for the preparation of an infusion solution (Avastin). It was approved in many countries and in the United States in 2004 and in the EU in 2005. Biosimilars have been approved in some countries and also in many countries. Structure and properties Bevacizumab is a recombinant, humanized … Bevacizumab
